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Objective: Infection with hepatitis C virus (HCV) is a serious public health problem worldwide. In
clinical studies, weight loss has been reported in 11% to 29% of patients treated with pegylated
interferon-a-2a/2b. Few reports have tried to explain such a weight loss. The aim of this study was
to evaluate nutritional status, body composition, and resting energy expenditure (REE) in patients
with chronic hepatitis C before and during treatment with pegylated interferon and ribavirin.
Methods: This was a prospective study with the evaluation of patients with hepatitis C virus before
and after 12 wk of treatment with pegylated interferon and ribavirin. The evaluation consisted of
anthropometry (weight, height, body mass index, and waist circumference), and body composition
was determined by bioelectrical impedance analysis. The REE of each individual was obtained by
indirect calorimetry. To compare the two phases of treatment, the Wilcoxon test was used. The
signiﬁcance level was 5%.
Results: Subjects had signiﬁcant weight loss during treatment with a consequent decrease in body
mass index. This weight decrease was accompanied by a signiﬁcant decrease in body fat and no
decrease in fat-free mass. There was a signiﬁcant decrease in energy intake as assessed by 24-h
recall. However, there was no change in REE and in REE corrected for fat-free mass.
Conclusion: Our study of patients with hepatitis C treatment showed that these patients had
signiﬁcant weight loss and this was not associated with changes in energy expenditure. However,
we observed a signiﬁcant decrease in energy intake, pointing to a possible need for intervention
measures to decrease the damage.
 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Infection with hepatitis C virus (HCV) is a serious public
health problemworldwide [1] and is considered the major cause
of chronic liver disease, cirrhosis, and death in the ﬁnal stages of
liver disease in the United States and in most Western countries.
It is estimated that approximately 180 million people around the
world are infected with HCV [2].
Currently, the standard treatment for chronic HCV infection is
a combination of pegylated interferon (PEG-IFN) a-2a or a-2b
and ribavirin. In clinical studies, weight loss has been reported inFAEPEX (Fund to Support
of Improvement of Higher
ax: þ55-19-3521-8566.
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sevier OA license.13% to 20% of patients treated with PEG-IFN a-2a and 11% to 29%
in patients treated with PEG-IFN a-2b [3–5], demonstrating an
important and predictable biological response to treatment [6].
However, the actual mechanisms of these disorders have not yet
been clariﬁed; it is not known if chronic HCV infection affects
energy expenditure or if PEG-IFN therapy affects the resting
metabolic rate of these patients [7].
Several studies have demonstrated that patients on standard
therapy have side effects, such as fatigue, inﬂuenzalike symptoms
(fever, myalgia, headache), insomnia, nausea, alopecia, irrita-
bility, arthralgia, anorexia, weight loss, dermatitis, hematological
abnormalities including neutropenia, and neuropsychiatric
symptoms such as depression, many of which may affect nutri-
tional status [3].
The few reports that have explained the weight loss often
observed during the current standard treatment of chronic HCV
with PEG-IFN and ribavirin led us to the necessity of designing
Table 1
Baseline characteristics of subjects evaluated
Characteristics Values
Gender, n (%)
Male 30 (71.4)
Female 12 (28.6)
Age (y) 46.3  10.8
Interferon, n (%)
a-2a 23 (54.8)
a-2b 19 (45.2)
Genotype, n (%)
1/4a 1 (2.4)
1a 9 (22)
1a1b 1 (2.4)
1b 13 (31.7)
3a 17 (41.5)
Staging, n (%)
1–2 17 (40.5)
3–4 25 (59.5)
Nutritional status according to BMI, n (%)
Eutrophic 17 (40.5)
Overweight 14 (33.3)
Obesity I 8 (19)
Obesity II 1 (2.4)
Obesity III 2 (4.8)
BMI, body mass index
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composition, and resting energy expenditure (REE) in patients
with chronic HCV before and during this treatment.
Materials and methods
Patients
This study prospectively evaluated the REE, nutritional status, and dietary
intake of 42 patients with HCV referred to the viral hepatitis outpatient unit at
the Gastrocenter (University of Campinas) and undergoing treatment with PEG-
IFN and ribavirin.
The inclusion criteria adopted were those in the ofﬁcial protocol for HCV
treatment from the Brazilian Ministry of Health. It is important to emphasize the
borderline criteria of an age of 70 y for inclusion, conﬁrmation of the disease, and
staging by liver biopsy.
The clinical exclusion criteria were the use of a weight-control dietary
supplement, participating in a diet or weight-losing program or other medical
treatment for weight loss, and having other chronic liver diseases such as
hepatitis B, Wilson’s disease, hemochromatosis, autoimmune liver disease,
decompensated cirrhosis, hepatocellular carcinoma, human immunodeﬁciency
viral infection, severe heart disease, cancer, active thyroid disease, uncontrolled
psychotic seizures, schizophrenia, severe depression without clinical control,
pregnancy, alcohol abuse, and the active use of injected drugs.
All subjects were evaluated before treatment, i.e., when the start of treatment
was determined by the medical team, and reassessed after 12 wk of therapy. The
patients had weekly injections of PEG-IFN a-2a (180 mg) or a 2b (1.5 mg/kg) plus
ribavirin (1000 to 1250 mg/d).
No patients had any clinical evidence of ascites or ﬂuid retention.
Data collection was conducted from March 2009 to December 2010.
Ethical considerations
The study was approved by the research ethics committee at the Faculty of
Medical Sciences, University of Campinas and written informed consent was
obtained from each participant after the purpose of the studywas fully explained.
Assessment of nutritional status
Anthropometric analysis was done under fasting conditions. Body height and
weight were measured and body mass index (BMI) was calculated [8]. A ﬂexible
tape was used to measure the circumference of the arm (midarm circumference)
while the arm was hanging relaxed. The measurement was taken midway
between the tip of the acromion and the olecranon process. Triceps skinfold
thickness was measured to the nearest millimeter using a Lange caliper (Santa
Cruz, CA, USA). These were measured on the dominant side of the body, with the
patient standing in a relaxed position. Muscular midarm circumference was
calculated by the formula: muscular midarm circumference (cm) ¼ midarm
circumference  p  [triceps skinfold thickness/10]. The abdominal circumfer-
ence was measured at the midpoint between the iliac crest and the last rib.
Body composition
Body composition was measured by bipolar bioelectrical impedance analysis
with an alternating electric current (50 mA) at two frequencies, 1 MHz and 5 kHz,
as previously described and validated by Boulier et al. [9].
A portable impedance analyzer (Biodynamics 310, Seattle, WA, USA) was
equipped with a microprocessor; a computer was used to calculate the imped-
ance and body composition. Measurements were taken in the morning, under
fasting conditions. The subjects had been supine for 10 min, with their arms
relaxed at the sides but not touching the body. Fat-freemass (FFM)was expressed
in kilograms and total body fat in percentages.
Resting energy expenditure
The resting energy expenditure (REE) of each participant was obtained by
indirect calorimetry in the metabolic unit of the Department of Clinical Medicine,
Faculty of Medical Sciences, University of Campinas. The procedure was per-
formed in the morning in a roomwith controlled temperature, low light, and no
noise. After a 30-min rest in the supine position, measurements were taken using
a canopy, open-circuit indirect calorimeter (model 29N, Medics Vmax, Yorba
Linda, CA, USA). After equilibrium was reached (about 10 min), respiratory
exchanges were monitored continuously over a 30-min period: data were
obtained every minute and averaged over the 30 min. The systemwas calibrated
immediately before each measurement with two standard gases. The REE was
calculated from the oxygen consumption rate and the carbon dioxide productionrate. The REE was also expressed as a ratio of FFM (REE/FFM) in kilocalories per
kilogram of FFM and for 24-h.
Nutritional counseling/food intake
All subjects were free-living and were instructed to consume their habitual
diets during the treatment. However, before the start of treatment, a 24-h recall
was performed by the nutritionist responsible for this study andwho had general
guidelines on healthy eating. Patients were followed up monthly. Four of the
eutropic patients began during the study to have severe weight loss, and thus, for
ethical reasons, were instructed to improve their alimentation. As a result, by the
end of the study none of these patients were malnourished.
The 24-h recall was performed before and after 12 wk of starting treatment.
The diet composition was quantiﬁed by NutWin 1.5 (Federal University of S~ao
Paulo, S~ao Paulo, Brazil). To minimize inaccuracies in the 24-h recall, the inter-
viewer was always the nutritionist responsible for this study. The researcher
attempted to clarify the information provided by the subjects and all 24-h recalls
were analyzed by the same researcher.
Statistical analysis
All data are expressed as mean  standard deviation. The comparison of data
between the two times of treatment (before treatment and at 12 wk) was per-
formed using the Wilcoxon test. The Mann-Whitney test was used to compare
the variables between two groups (liver ﬁbrosis stages 1 to 2 and 3 to 4).
The analysis of correlation between weight loss and energy intake was per-
formed by the Spearman correlation coefﬁcient.
All analyses were carried out using SAS 9.1.3 forWindows (SAS Institute, Cary,
NC, USA) and statistical signiﬁcance was accepted at P < 0.05.
Results
Forty-two patients with chronic hepatitis C treated with PEG-
IFN and ribavirin participated in this study.
At the baseline of the study, 40.5%were eutrophic, 33.3%were
overweight, and 26.2% were obese. The characteristics of the
study population are listed in Table 1.
The differences in nutritional status, energy intake, and REE of
the patients before and during drug therapy for the treatment of
hepatitis C are presented in Table 2. The subjects had signiﬁcant
weight loss during the treatment with a consequent decrease in
BMI. This weight decrease was accompanied by a signiﬁcant
decrease in body fat and no decrease in FFM.
Table 2
Differences in nutritional status and resting energy expenditure of patients
before and during hepatitis C treatment
Baseline/before
treatment
Week 12 of
treatment
P*
Mean  SD Mean  SD
Weight (kg) 79.1  15.6 75.7  15 <0.001
BMI (kg/m2) 27.5  5.2 26.3  5 <0.001
Body fat (%) 29  8.2 26.7  7.8 <0.001
FFM (kg) 55.6  10 55  10.2 0.210
Abdominal circumference (cm) 97.8  14.3 95.5  14.1 <0.001
Triceps skinfold (mm) 18  8.1 15.6  7 <0.001
Muscular midarm circumference 27  2.9 26.5  2.8 0.008
REE (kcal) 1168.2  303 1151.3  249 0.670
REE (kcal)/FFM (kg) 20.9  3.7 21.1  3.7 0.864
BMI, body mass index; FFM, fat-free mass; REE, resting energy expenditure
* Wilcoxon test. Statistical signiﬁcance was accepted at P < 0.05.
Table 4
Macronutrient intakes of patients before and during hepatitis C treatment
Baseline/before
treatment
Week 12 of
treatment
P*
Mean  SD Mean  SD
Carbohydrate (g) 270.3  116.6 243.2  88 0.194
Protein (g) 84  35.6 75.5  34.1 0.040
Fat (g) 80.7  38.2 65.3  29.7 0.009
* Wilcoxon test. Statistical signiﬁcance was accepted at P < 0.05.
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and abdominal circumference also were signiﬁcantly decreased
(Table 2).
There was a signiﬁcant decrease in energy intake assessed by
the 24-h recall (Table 3), without a signiﬁcant change in the
percentage of the distribution of macronutrients but with
a signiﬁcant decrease in the consumption of proteins and fat
(Table 4). However, there were no changes in REE and REE cor-
rected for FFM (Table 2).
A slightly signiﬁcant correlation was found between weight
loss and a decrease in energy intake (Fig. 1).
From the standpoint of the degree of hepatic ﬁbrosis, i.e., the
stage of hepatitis C, compared with the weight, REE and REE
adjusted for FFM, and the energy intake of patients before and
during drug therapy, we observed no differences for the variables
analyzed (Table 5).Discussion
Weight loss is a side effect commonly seen in patients on
therapy with PEG-IFN and ribavirin, ranging from 12% to 29% [4,
5], which can reach 90% of individuals [10], with probable
recovery after treatment [11]. However, the mechanisms of these
disorders have not yet been elucidated, including the inﬂuence of
therapy on REE. Therefore, we attempted in this study to
contribute to a better understanding of this phenomenon.
Hamer [10] reported that 93% of patients had weight loss and
decreased energy intake during therapy with PEG-IFN a-2a and
ribavirin. In comparison, in the present study, 88% of patients
had weight loss and a decreased energy intake in the 12-wk
period, with no changes in REE.
In a randomized trial, Manns et al. [4] evaluated patients who
received PEG-IFN a-2b 1.5 mg/kg each week plus ribavirin
800 mg/d or PEG-IFN a-2b 1.5 mg/kg per week for 4 wk and thenTable 3
Dietary intake of patients before and during hepatitis C treatment
Baseline/before
treatment
Week 12 of
treatment
P*
Mean  SD Mean  SD
Energy intake (kcal) 2131  890 1834  699 0.012
Carbohydrate (%) 50.6  6 52.8  6.2 0.06
Protein (%) 16.3  4.6 16.2  3.4 0.98
Fat (%) 33.1  5.5 31  5.8 0.12
* Wilcoxon test. Statistical signiﬁcance was accepted at P < 0.05.0.5 mg/kg per week plus ribavirin 1000 to 1200 mg/d for 48 wk,
and the percentages of patients who had weight loss were 29%
and 17%, respectively.
Seyam et al. [6] observed that 91.2% of patients treated with
PEG-INF a-2b lost weight at 4 wk, 93.7% at 12 wk, and 94.7% at
24 wk.
Conjeevaram et al. [11] found decreases in BMI and homeo-
stasis model assessment (HOMA-IR) values in non-responder
patients, those with relapse, and patients who achieved a sus-
tained virologic response (SVR). However, these values reboun-
ded after the end or the suspension of treatment mainly in
non-responders and those who relapsed. This was probably
because there was a decrease in the inﬂammatory process of the
liver with a consequent decrease of inﬂammatory cytokines
during treatment and maintenance in those with SVR. A similar
result was observed by Suwantarat et al. [12], in which patients
who achieved SVR had signiﬁcant weight loss compared with
those without SVR, but this association is controversial. The
weight loss was maintained during drug therapy, but these
patients began to gain weight once therapy was stopped.
This decline in nutritional status may be related to the effect
of the side effects of the treatment, which include fatigue, loss of
appetite, and nausea.
Therefore, weight loss in patients during the treatment of
chronic hepatitis C with PEG-IFN and ribavirin, besides being
a frequent symptom [6,10–12], is an ongoing concern for experts
who monitor these patients during the therapy cited [13].
In our study, although weight loss occurred, we observed that
none was classiﬁed as malnourished according to the BMI in the
nutritional assessment (data not shown), possibly because theyFig. 1. Correlation between weight loss and changes in energy intake in patients
with hepatitis C during the standard treatment (r ¼ 0.306, P ¼ 0.0517).
Table 5
Comparison between stages of hepatic ﬁbrosis concerning weight, REE and REE adjusted for FFM, and energy intake of patients before and during hepatitis C treatment
Staging Baseline/before treatment P Week 12 of treatment P*
Mean  SD Mean  SD
1–2 3–4 1–2 3–4
Weight (kg) 78.7  19 80.3  13.8 0.61 75.5  18.5 77.1  12.8 0.62
REE (kcal) 1178.1  354.5 1141.1  277.7 0.944 1185.6  332.3 1118.2  180.7 0.734
REE (kcal)/FFM (kg) 21.4  4.5 20.5  3.2 0.591 22  4.4 20.5  3.1 0.113
Energy intake (kcal) 1981  817.5 2109.4  796.6 0.591 1792.9  484 1733.5  704.4 0.515
FFM, fat-free mass; REE, resting energy expenditure
* Mann-Whitney test. Statistical signiﬁcance was accepted at P < 0.05.
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provided guidance on how to deal with the symptoms during
treatment, with the aim of decreasing damage.
Regarding body composition, although there was no decrease
in FFM, a signiﬁcant loss in body fat was observed. We observed
a decrease of approximately 14% of caloric intake, but with
a proper proportional distribution of macronutrients (Table 3),
i.e., there was no restriction on a speciﬁc macronutrient, which
probably contributed to the preservation of FFM. Also, at the
baseline, i.e., before starting treatment, all patients received
general guidelines on how to eat healthily. None of the patients
practiced physical activity during the treatment. The main
reason for non-physical activity was the presence of side effects
such as anemia, fatigue, and arthralgia, which are very common
during PEG-INF use.
From the standpoint of the body composition data, similar
results have been described by other investigators. Iwasa et al.
[14] reported a signiﬁcant decrease in visceral fat and total body
fat percentage in patients with chronic hepatitis C after 3 and
6 mo of calorie restriction (30 kcal/kg of ideal bodyweight).
Further, Redman et al. [15] found a signiﬁcant decrease in body
fat and FFM in individuals after 3 and 6 mo of calorie restriction
(calorie decreases of 17.8% and 19.5%, respectively) with or
without exercise.
However, there are no other studies that explain the signiﬁ-
cant loss of body fat in these patients. Because most patients
were overweight or obese, the calorie restriction likely caused
this decrease.
Another point to consider is the possible decrease of
inﬂammation characterized by a decrease in alanine amino-
transferase [14,16] during treatment that may reﬂect the
decrease in circulating inﬂammatory cytokines [17], which in
turn could contribute to decreased total body fat.
Although in our study there was no change in REE, there was
a decrease in energy intake, which partly explains the weight
loss (Fig. 1). Other studies showing the relation of inﬂammatory
cytokines to weight loss and a decrease in body fat (lipolysis)
need to be carried out in patients with chronic hepatitis C.
The weight loss may be related to the adverse effects of
treatment, such as a loss of appetite, with the consequent
decrease in energy intake and disease progression rather than
changes in REE.
Patients receiving treatment with PEG-IFN plus ribavirin for
chronic hepatitis C must be monitored closely for side effects.
These events can bemanaged effectively tomaximize the patients’
adherence and thus the chance for treatment success [18].
The addition of the direct-acting antiviral agent to standard
treatment seems to have the potential to double the sustained
response rate compared with that recorded with standard
treatment alone in treatment-naive patients with genotype-1
[19]. However, these gains will be partly offset by newchallenges in viral resistance and increased adverse events [20],
especially in weight loss.
A limitation in the study is the potential inaccuracies associ-
ated with the 24-h recall. This method depends on the memory
of the interviewee who may not recall information precisely.
Conversely, it is a quick and easy questionnaire response, the
patients do not need to be literate as they are interviewed, and
the test does not inﬂuence the feeding patterns of the patient.
However, any estimation of intake and portion sizes may have
a degree of error.
The ﬁnding obtained in our study is of great signiﬁcance,
because we cannot attribute the changes in REE to the drugs
used. The fact that we demonstrated a decrease in energy intake
in the subjects of this study reinforces the need for greater
support for these individuals from a nutritional standpoint,
emphasizing the inclusion of the nutritional professional in the
team who follows these patients.
The results have an important consequence from the clinical
point of view, because the standard treatment will used for
several years, even after the adventof direct-acting antivirals such
as the protease inhibitors recently approved for clinical use [21].
In conclusion, our study of patients with hepatitis C treatment
showed that these patients had a signiﬁcant weight loss and this
was not associated with changes in energy expenditure.
However, we observed a signiﬁcant decrease in energy intake,
pointing to a possible need for intervention measures to
decrease the damage.Acknowledgments
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